Mary Stoll is the new senior director of clinical development Soliton, a medical device manufacturer with a novel and proprietary acoustic pulse platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center. Stoll will be responsible for direct oversight of all clinical activities of the company’s Rapid Acoustic Pulse (RAP) device for tattoo removal, improvement in the appearance of cellulite and keloid scarring, and additional pipeline indications. She formerly served as senior director of clinical operations at Cytrellis Biosystems where she oversaw and led all clinical operations activities for a new technology targeting skin laxity. Prior to her tenure with Cytrellis, Stoll was the executive director of clinical services at Cynosure.
“We believe Mary’s directly related clinical dermatology experience will help Soliton accelerate and improve our research and development activities. It is evident that Mary’s experience directly overlaps the role she will fill at Soliton,” said Joe Tanner, CEO of Soliton. “More importantly, we believe she is exactly the right fit within our culture of strong teamwork.”
